Background: Brain and acute leukemia, cytoplasmic (BAALC) gene is identified on chromosome 8q22.3 and implicated in normal hematopoiesis. BAALC gene overexpression is associated with poor outcome. Methods: We aimed to evaluate BAALC expression in de novo Egyptian acute myeloid leukemia (AML) cases and determine its prognostic value. We recruited 70 patients with de novo AML diagnosed and treated at clinical pathology and medical oncology departments, fulfilling inclusion criteria in our prospective study and evaluated BAALC expression level. Patients received induction therapy. The Institutional Review Board approved our study. Results: The mean age was 39.2 years ± 11.87, (18–60) with a male/female ratio of 3/2. The cutoff value of BAALC as a prognostic factor was 2.11 with sensitivity (86.1%), specificity (80%), positive predictive value (88.6%), and negative predictive value (76.2%.) (P 0.001), 43 (61.4%) patients had high BAALC expression. Seventy-two percent of patients in the low BAALC group achieved complete remission (CR) compared to 42.1% in high BAALC expression group (P = 0.03). Patients with low BAALC (123.1 ± 4.9) had longer mean survival time than high BAALC group (45.85 ± 5.1) (P = 0.000). Conclusion: High-BAALC expression is an adverse prognostic factor, with a higher risk of relapse, lower CR rates, and lower survival in Egyptian de novo AML patients.
展开▼
机译：背景：脑和急性白血病，细胞质（Baalc）基因在染色体上鉴定在8Q22.3上，并涉及正常血小杂物。 Baalc基因过表达与结果不佳相关。方法：我们旨在评估De Novo埃及急性髓性白血病（AML）病例的BAALC表达，并确定其预后价值。我们在临床病理和医学肿瘤科学部门致诊断和治疗的DE Novo AML患者，在我们的前瞻性研究中履行纳入标准并评估了BAALC表达水平。患者接受诱导治疗。机构审查委员会批准了我们的研究。结果：平均年龄为39.2岁±11.87，（18-60），男性/女性比例为3/2。作为预后因子的BAALC的截止值为2.11，灵敏度（86.1％），特异性（80％），阳性预测值（88.6％）和阴性预测值（76.2％）（P <0.001），43（61.4 ％）患者具有高BAALC表达。在高BaAlc表达组中，七十二名百分之七患者在低BAALC组患者中获得了完整的缓解（CR）（P = 0.03）。低Baalc（123.1±4.9）的患者的平均存活时间比高BAALC组（45.85±5.1）（P = 0.000）。结论：高Baalc表达是一种不良预后因素，具有更高的复发风险，较低的CR率和埃及De Novo AML患者的生存率降低。
展开▼
